vTv Therapeutics Inc. (VTVT) Downgraded by Zacks Investment Research to “Hold”
vTv Therapeutics Inc. (NASDAQ:VTVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
Several other research firms have also issued reports on VTVT. HC Wainwright assumed coverage on shares of vTv Therapeutics in a report on Monday, September 26th. They issued a “buy” rating and a $13.00 target price for the company. Piper Jaffray Cos. reissued an “overweight” rating and issued a $24.00 target price on shares of vTv Therapeutics in a report on Saturday, October 15th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $15.00 target price on shares of vTv Therapeutics in a report on Friday, August 19th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. vTv Therapeutics presently has a consensus rating of “Buy” and an average price target of $15.70.
Shares of vTv Therapeutics (NASDAQ:VTVT) traded down 0.3541% during midday trading on Tuesday, reaching $5.6001. 623 shares of the company’s stock traded hands. vTv Therapeutics has a one year low of $4.69 and a one year high of $7.70. The firm’s market capitalization is $54.28 million. The stock’s 50-day moving average price is $5.94 and its 200 day moving average price is $5.96.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Financial Market News and is the sole property of of Financial Market News. If you are accessing this news story on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The original version of this news story can be accessed at http://www.financial-market-news.com/vtv-therapeutics-inc-vtvt-downgraded-by-zacks-investment-research-to-hold/1208453/.
A number of large investors have recently made changes to their positions in VTVT. Sphera Funds Management LTD. bought a new stake in shares of vTv Therapeutics during the third quarter worth about $1,438,000. Northern Trust Corp raised its stake in shares of vTv Therapeutics by 0.8% in the third quarter. Northern Trust Corp now owns 81,262 shares of the company’s stock worth $584,000 after buying an additional 622 shares during the period. Ameriprise Financial Inc. raised its stake in shares of vTv Therapeutics by 0.4% in the third quarter. Ameriprise Financial Inc. now owns 162,080 shares of the company’s stock worth $1,165,000 after buying an additional 596 shares during the period. Bank of New York Mellon Corp raised its stake in shares of vTv Therapeutics by 7.6% in the third quarter. Bank of New York Mellon Corp now owns 21,278 shares of the company’s stock worth $153,000 after buying an additional 1,504 shares during the period. Finally, State Street Corp raised its stake in shares of vTv Therapeutics by 37.5% in the second quarter. State Street Corp now owns 84,222 shares of the company’s stock worth $488,000 after buying an additional 22,983 shares during the period. 12.41% of the stock is owned by institutional investors and hedge funds.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.